<DOC>
	<DOCNO>NCT01997892</DOCNO>
	<brief_summary>To describe time course hemoglobin concentration EU hemodialysis patient switch methoxy polyethylene glycol-epoetin beta ( PEG epoetin beta ; Mircera ) darbepoetin alfa ( Aranesp ) .</brief_summary>
	<brief_title>TRANSFORM - Observational Cohort Study Darbepoetin Alfa Use European Union ( EU ) Hemodialysis Patients Switched From PEG Epoetin Beta</brief_title>
	<detailed_description>This multi-centre , observational cohort study EU hemodialysis patient whose erythropoiesis stimulate agent ( ESA ) therapy switch PEG epoetin beta darbepoetin alfa . Data collect period span 14 week prior switch 26 week post-switch .</detailed_description>
	<mesh_term>Darbepoetin alfa</mesh_term>
	<mesh_term>Epoetin Alfa</mesh_term>
	<criteria>Patients &gt; 18 year age . CKD diagnosis , receive hemodialysis Received PEG epoetin beta 14weeks prior switch darbepoetin alfa receive least one dose darbepoetin alfa .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>June 2014</verification_date>
	<keyword>CKD</keyword>
	<keyword>Darbepoetin Alfa</keyword>
	<keyword>Dialysis</keyword>
	<keyword>Hemodialysis</keyword>
	<keyword>Anemia</keyword>
	<keyword>Peg epoetin beta</keyword>
</DOC>